MedPath

Prasterone

Generic Name
Prasterone
Brand Names
Intrarosa
Drug Type
Small Molecule
Chemical Formula
C19H28O2
CAS Number
53-43-0
Unique Ingredient Identifier
459AG36T1B
Background

Prasterone, also known as dehydroepiandrosterone (DHEA) is a major C19 steroid produced by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (DHEA) can be converted to testosterone; androstenedione; estradiol; and estrone. Most of DHEA is sulfated (dehydroepiandrosterone sulfate) before secretion.

In the United States, DHEA or DHEAS have been advertised with claims that they may be beneficial for a wide variety of ailments. DHEA and DHEAS are readily available in the United States, where they are marketed as over-the-counter dietary supplements. In November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

In Canada, a prescription is required to buy DHEA.

Indication

DHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids).

DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.

Associated Conditions
Moderate Dyspareunia, Severe Dyspareunia

Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI

Phase 4
Conditions
Subfertility
Interventions
Drug: Placebo 1
Drug: Placebo 2
First Posted Date
2016-05-10
Last Posted Date
2018-01-03
Lead Sponsor
Cairo University
Target Recruit Count
230
Registration Number
NCT02766764
Locations
🇪🇬

Cairo university hospitals, Cairo, Egypt

🇪🇬

Dar AlTeb subfertility centre, Cairo, Egypt

Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response

Phase 3
Conditions
Subfertility
Interventions
Drug: Growth Hormone-Releasing Hormone
Drug: Placebo 2
Drug: Placebo 1
First Posted Date
2016-04-13
Last Posted Date
2016-07-06
Lead Sponsor
Cairo University
Target Recruit Count
210
Registration Number
NCT02736591
Locations
🇪🇬

Cairo University Hospitals, Cairo, Egypt

🇪🇬

Dar AlTeb subfertility centre, Cairo, Egypt

DHEA in Synovial Sarcoma Patients

Phase 1
Terminated
Conditions
Synovial Sarcoma
Sarcoma, Synovial
Interventions
Other: FACT-67 validated survey
First Posted Date
2016-02-17
Last Posted Date
2019-09-09
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
11
Registration Number
NCT02683148
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

DHEA Versus Placebo in Women With Poor Ovarian Response

Phase 3
Conditions
Subfertility
Interventions
Drug: Placebo
First Posted Date
2015-09-28
Last Posted Date
2016-07-06
Lead Sponsor
Cairo University
Target Recruit Count
440
Registration Number
NCT02561793
Locations
🇪🇬

Dar AlTeb subfertility centre, Giza, Egypt

🇪🇬

Cairo University Hospitals, Cairo, Egypt

Testosterone Gel in Poor Responders Undergoing IVF

Not Applicable
Withdrawn
Conditions
Infertility
Interventions
First Posted Date
2015-09-15
Last Posted Date
2017-04-18
Lead Sponsor
Vietnam National University
Registration Number
NCT02549690
Locations
🇻🇳

My Duc Hospital, Ho Chi Minh City, Ward 13. Tan Binh District, Vietnam

Effect of DHEA on Patients With Poor Ovarian Responds

Not Applicable
Recruiting
Conditions
Subfertility
Interventions
Other: placebo(medical starch)
First Posted Date
2015-05-04
Last Posted Date
2023-07-20
Lead Sponsor
The Affiliated Hospital of Inner Mongolia Medical University
Target Recruit Count
350
Registration Number
NCT02432248
Locations
🇨🇳

The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China

The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders

Phase 4
Conditions
Infertility
Interventions
First Posted Date
2015-02-06
Last Posted Date
2015-11-17
Lead Sponsor
ShangHai Ji Ai Genetics & IVF Institute
Target Recruit Count
50
Registration Number
NCT02357472
Locations
🇨🇳

Ji Ai Genetics and IVF center, Shang Hai, Shanghai, China

Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve

Phase 1
Completed
Conditions
Healthy Women
Infertility, Female
Interventions
Drug: Another Androgenic Agent (VRaA)
Drug: Fixed combination of 2 androgenic agents (VR2A)
First Posted Date
2014-10-20
Last Posted Date
2019-05-29
Lead Sponsor
Laboratorios Andromaco S.A.
Target Recruit Count
94
Registration Number
NCT02268032
Locations
🇨🇱

Mother and Health Research Institute (IDIMI), Faculty of Medicine, University of Chile, Santiago, International, Chile

Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?

Phase 3
Completed
Conditions
Subfertility
Interventions
First Posted Date
2014-05-30
Last Posted Date
2015-05-19
Lead Sponsor
Cairo University
Target Recruit Count
140
Registration Number
NCT02151006
Locations
🇪🇬

Dar AlTeb subfertility centre, Giza, Egypt

🇪🇬

Cairo University Hospitals, Cairo, Egypt

Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve

Phase 3
Completed
Conditions
Dehydroepiandrosterone
DHEAS
Gene Expression of Cumulus Cells.
Ovarian Hyper-stimulation Protocol.
Artificial Reproduction Technology.
Interventions
First Posted Date
2014-05-29
Last Posted Date
2014-05-29
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
40
Registration Number
NCT02150330
Locations
🇨🇳

Taipei Veteran General Hospital, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath